Novartis expects to eliminate US tariff exposure by mid‑2026, CEO tells CNBC
Jan 20 (Reuters) – Novartis (NOVN.S), opens new tab CEO Vas Narasimhan instructed CNBC on Tuesday he expects the drugmaker’s settlement with the U.S. authorities and its increasing manufacturing footprint…